Diurnal Group - Termination of coverage
Edison Investment Research is terminating coverage on Vivesto (VIVE), Diurnal Group (DNL), Palace Capital (PCA), Primary Health Properties (PHP),...
210 Views
Diurnal Group - Proposed acquisition by Neurocrine Biosciences
Diurnal has announced that it has agreed to an acquisition by Neurocrine Biosciences (US-based biopharmaceutical player) for a cash consideration...
658 Views
Diurnal Group - Alkindi sales underpin top-line growth
Diurnal announced a trading update for the 12-month period ending June 2022, reporting top-line results broadly in line with consensus estimates....
663 Views
Diurnal Group - First patient dosed in the US CONnECT study
Diurnal has dosed the first patient in its pivotal Phase III CONnECT clinical trial assessing DNL-0200/Efmody in adults with congenital adrenal...
668 Views
Diurnal Group - Leveraging the known pathway
Diurnal has announced the extension of its existing marketing and distribution agreement with EffRx Pharmaceuticals, to include Efmody (in addition...
7 Views